Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease

Affiliations

• ¹ Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany.
• ² Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
• ³ Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, 513 Parnassus Avenue, San Francisco, CA, USA.
• ⁴ Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
• ⁵ Institute of Pathology, University of Greifswald, Greifswald, Germany.
• ⁶ Experimental Pathology Unit, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
• ⁷ School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
• ⁸ School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
• ⁹ Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
• ¹⁰ Department of Thyroid and Breast Surgery, The 960Th Hospital of the PLA, Jinan, 250031, China.
• ¹¹ National Institute of Gastroenterology, IRCCS- Saverio de Bellis Research Hospital, Castellana Grotte, Italy.
• ¹² University of Hawaii Cancer Center, Honolulu, HI, USA.
• ¹³ Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, Regensburg, Germany. katja.evert@ukr.de.